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Alzheimer’s disease (AD) is the leading subtype
of dementia. In the United States in 2003, it was
the fifth and eighth leading cause of death in
women and men aged ≥ 65 years, respectively.1
Taiwan became an aging country in 1993 (≥ 7%
of the population aged ≥ 65 years, as defined by
the World Health Organization), and the aged
population exceeded 10% at the end of 2006. As
medical care advanced over time in Taiwan, life
expectancy reached 75 and 81 years for men and
women, respectively, in 2007.2 This has led to the
observation of an increasing number of demen-
tia cases. In Taiwan, dementia affects more than
160,000 people according to data from the
Association of Dementia in Taiwan in 2009. This
is twice as many as 15 years ago. There are about
5 million AD patients in the United States and
this is estimated to rise to 16 million in 40
years.3 In Western countries, AD affects 1–3% of
people aged 60–64 years, and 3–12% of people
aged 70–80 years. This proportion increases to
25–35% for people older than 85 years.4 In con-
trast, the prevalence of dementia in Taiwanese
people aged ≥ 65 years was estimated to be 2–4%
by 2000, which is lower than that in other devel-
oped countries.5 In addition, the actual number
is underestimated because: (1) the aging popula-
tion in Taiwan is composed mainly of people 
at a relatively younger age of 65–75 years; (2) 
the mortality rate is higher among those with 
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REVIEW ARTICLE
dementia than those without; (3) diagnosis of
dementia is complicated and it is easily over-
looked; and (4) genetic differences exist between
ethnic groups (e.g. there are fewer APOEe4 allele
carriers in Taiwan).5 Therefore, the actual preva-
lence of dementia in Taiwan is probably greater
than has been observed.
Dementia is categorized into a few subtypes
according to its causes. AD accounts for about
half of the affected population, followed by vas-
cular dementia (VaD) (20–25%), mixed dementia
(5–10%), Parkinson’s disease, dementia with Lewy
bodies, physical brain injury, Huntington’s dis-
ease, Creutzfeldt–Jacob disease, frontotemporal
dementia/Pick’s disease, and normal pressure
hydrocephalus.5,6 AD is also the most common
neurodegenerative disorder and affects 20–30
million individuals worldwide.7 AD has been
further categorized into two forms according to
its onset: sporadic cases (> 95%) with late-onset
disease, and autosomal-dominant mutation cases
(< 5%) with early onset.
The pathogenesis of AD includes the forma-
tion and deposition of amyloid β (Aβ), neurofib-
rillary tangles (assembled by hyperphosphorylated
Tau protein), and inflammation.8,9 Among these,
it is widely accepted that fibrillar Aβ plays an im-
portant role in AD pathogenesis through activa-
tion of microglia and stimulates the release of
inflammatory mediators, which lead to neuronal
dysfunction and subsequent cell death.10 However,
recent clinical evidence and animal studies have
revealed that astrocyte and microglial activation
may be an early event in AD, which occurs be-
fore the formation of Aβ.11–16 The importance of
inflammation on the progress of AD has been
emphasized. However, it is uncertain whether Aβ
and neurofibrillary tangles are causal factors of
AD. Current medical treatment for dementia
aims to improve cognitive and behavioral symp-
toms; therefore, it is essential to identify markers
for the early stage of dementia to prevent or halt
disease progress.
Factors associated with dementia include age,
sex, inflammation, genetic factors, comorbidity,
environmental factors, and lifestyle. Protective
factors include high education level, moderate
alcohol consumption, use of hormone replace-
ment therapy (HRT) for women, use of anti-
inflammatory drugs, and diet. Associations 
between these factors and dementia might vary
by disease subtype and are discussed in this 
review.
Methods
We performed searches of MEDLINE (http://
medline.cos.com) and PubMed (http://www.ncbi.
nlm.nih.gov/entrez/query.fcgi) to identify rele-
vant articles published between 1966 and 2009.
We also searched EMBASE (http://www.embase.
com) for articles published between 1991 and
2009.
Genetic Effects
Several studies have used candidate gene ap-
proaches to explore the association between ge-
netic variants and the risk of dementia. Among
these, the APOE gene is of great importance in the
majority of people with dementia, which mostly
are sporadic cases. The association between APOE
genotype and the risk of AD was first reported by
Corder et al in 1993.17 A Swedish twin study has
reported that 60–80% of AD is attributable to ge-
netic effects.18,19 For late-onset AD, genetic varia-
tions in the APOE gene play an important role.
For early-onset cases, APP, preselin (PS)-1, and PS-2
genes are of interest.20 As the number of APOEe4
alleles increases, the risk of late-onset AD in-
creases from 20% to 90%, and the mean age at
onset decreases from 84 to 68 years.17 A meta-
analysis has shown that the APOEe4 allele is a
major risk factor for AD in all ethnic groups for
men and women aged between 40 and 90 years.21
This association is stronger among Japanese than
Caucasians but weaker among African-Americans
and Hispanics.21 Even though the APOEe4 allele
has been related to an elevated risk of AD,22 only
50% of AD cases carry an APOEe4 allele.23 This
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reflects that genes other than APOE may play a
role in the pathogenesis of AD.
Inflammation is an important process in the
pathogenesis of AD, and recent studies have shown
that polymorphisms of one of the inflammatory
genes alone or in combination have comparable
effects on AD risk to those for the APOEe4 allele.
For example, IL-1a-889 allele T is associated sig-
nificantly with the risk of late-onset AD regardless
of the genotype of APOE.24 Homozygous variant
carriers of high-risk alleles, e.g. IL-1α-889 and 
IL-1β + 395325–27 or the combination of the
APOEe4 and high-risk allele of TNF-a,28 could
predict people at high risk of AD.29 These find-
ings reflect that the joint effect of inflammatory
and APOE genes may be better predictors of dis-
ease risk than APOE genotypes alone. In contrast
to the candidate gene approach, recent genome-
wide association studies30–32 have consistently
found that APOE is a significant risk factor for
dementia among Caucasians.
Age
The effects of aging and parental age at birth
have been linked to the risk of dementia. In the
United States and Europe, several cohort stud-
ies33–39 have shown that the risk of dementia and
AD increases with age. This association has been
observed in all subtypes of dementia in a Spanish
study.39 A meta-analysis that included 17 Chinese
studies has also shown that the prevalence of AD
and VaD increases with age.40 As a whole, the 
effect of aging is a relatively consistent risk factor
for dementia across various ethnic groups.
Relatively few studies have evaluated the asso-
ciation between parental age at birth and the risk
of dementia. Some studies have found that ad-
vanced parental age at birth is associated with an
increased risk of AD, probably because of chro-
mosomal abnormality.41–43 However, other stud-
ies have failed to replicate this association.44–46
Parental health status might vary significantly
between individuals and populations; therefore,
it may not be a reliable predictor for dementia.
Sex
Sex is an important risk factor for AD among eld-
erly people. A Dutch follow-up study has found
that the incidence of AD in women is higher than
that in men after the age of 85 years.47 However,
there are no sex differences in rates or risk for
VaD. The same team has also reported that the
risk of AD declines in men but not in women after
the age of 90 years.48 The overall incidence of
VaD is lower in women than in men.48 A meta-
analysis that included only Chinese populations
has shown a higher prevalence of AD, but not
VaD, among women as compared with men aged
≥ 60 years.40 The above findings can be explained
by a protective effect of estrogen for pre-
menopausal women, and earlier death for men
from cardiovascular disease.47 In contrast, the as-
sociation between sex and risk of dementia has
been shown to be not significant in Italian and
Spanish populations.39,49 Several factors might
complicate this association, e.g. sex steroid hor-
mones, lifestyle, ethnicity, and genetic poly-
morphisms of sex-related genes. Therefore, it is
important to consider various risk factors while
the association between sex and risk of dementia
is explored.
Physical Activity
The association between physical activity and
risk of dementia has been explored extensively.
Some cohort studies have observed that physical
activity is associated positively with cognitive
function among older people.50,51 Other studies
have found that physical activity is associated with
a reduction of 30–50% in cognitive decline.52–54
A meta-analysis that included 30 randomized trials
has found that exercise training has a positive effect
on cognitive function.55 A randomized trial in the
elderly conducted after the meta-analysis has found
that 24 weeks of physical activity intervention
may improve cognitive function.56 Furthermore,
a cross-sectional study in community-dwelling
residents aged 70–79 years has shown that high
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levels of recreational activity are associated sig-
nificantly with lower levels of the inflammatory
markers interleukin-6 and C-reactive protein.57
Such potential benefits of increased physical ac-
tivity on inflammatory markers will need to be
confirmed in clinical trials. The protective effect
of physical activity might be a result of reduced
vascular risk and obesity, lower levels of inflam-
matory markers, enhanced fitness, neuronal
health, and physical function, as well as positive
behavior.55,58 In a follow-up study in the United
States, individuals who participated in at least
four physical activities within 2 weeks before
study recruitment had a significantly lower risk
of dementia compared with those who engaged
in only one or no activity.59 This association was
significant among APOEe4 allele non-carriers,
but absent from APOEe4 allele carriers.59 As a
whole, most previous studies have supported the
notion that physical activity can reduce the risk
of dementia, probably through improvement of
cognitive function and overall health status.
Different measurements of cognition, various
lengths of study period, and different subject
characteristics have been used to evaluate the 
effect of physical activity on the risk of dementia,
and these might explain the inconsistency of pre-
vious findings.
Smoking
The effect of smoking on dementia risk is contro-
versial. A recent meta-analysis has shown that
current smoking is associated significantly with
an increased risk of AD but not with VaD and
cognitive decline.60 Two follow-up studies61,62 in
the United States and one in China63 have re-
ported a significant association between current
smokers and the risk of dementia. This association
was not significant among former smokers.61,62
Previous inconsistent findings possibly have re-
sulted from survival bias, some potential issues for
case–control studies (e.g. recall bias, under- and
overestimation of smoking), and failure to strat-
ify the subjects by smoking status (current and
former smoking) in the analysis. Smoking could
be a potential confounder for the association of
cerebrovascular diseases with dementia. However,
cerebrovascular diseases have not been explored
consistently in previous studies. Future studies
using a follow-up design will be able to provide
more accurate data on cigarette smoking. Stratifi-
cation by smoking status (current vs. former smok-
ing) is warranted to elucidate this association.
Drugs
Several drugs are related to the risk of dementia.
This review only discusses some commonly used
drugs. A French study has shown that former, but
not current use of benzodiazepines, was related to
an increased risk of dementia in a nested case–
control study.64 Conversely, some drugs might
be beneficial in lowering dementia risk. Statins
(HMG-CoA reductase inhibitors) are used widely
to lower the level of cholesterol, especially low-
density lipoprotein cholesterol, in patients with
cardiovascular disease. In a follow-up study of an
elderly population in the United States, statin use
was associated inversely with the risk of preva-
lent dementia, but not for incident dementia or
AD.65 Similarly, a recent observational study has
found that simvastatin significantly reduces the
risk of dementia among individuals over 65 years
of age.66 Statins seem to reduce the risk of de-
mentia effectively through an anti-inflammatory
mechanism by lowering the level of cholesterol,
and isoprenylation.66 More randomized clinical
trials are needed to confirm the effect of statins,
as well as studies stratified by dementia subtypes
(e.g. VaD and mixed type) and age of dementia
onset. Four clinical trials have investigated the ef-
fects of antihypertensive drugs on the risk of de-
mentia. The Syst-Eur trial67 has shown that active
treatment with nitrendipine, with the possible
addition of enalapril and/or hydrochloroth-
iazide, could lower the incidence of dementia by
50% as compared with the placebo group. The
PROGRESS study has found that active treatment
with perindopril with/without indapamide was
Dementia and risk factors
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associated significantly with a reduction in cogni-
tive decline as compared with the placebo group.68
However, the SCOPE study69 (candesartan with/
without hydrochlorothiazide vs. placebo) and
the SHEP trial70 (chlorthalidone with/without
atenolol or reserpine vs. placebo) have failed to
show a significant reduction in dementia inci-
dence. Other classes of antihypertensive drugs
(e.g. angiotensin-converting enzyme inhibitors,
angiotensin II receptor blockers, diuretics, and
calcium channel blockers) might lower the risk of
dementia.71 The findings from antihypertensive
drugs are inconclusive, which could be the result
of the different etiology of dementia subtypes, as
well as different pharmacokinetics and pharma-
codynamics. Previous studies mainly have ex-
plored overall dementia, and prospective studies
and clinical trials stratified by dementia subtypes
are needed to explore the effects of various drugs
on the risk of dementia.
Several studies have found an association be-
tween HRT and lower risk of AD among
women.72–77 The phenomenon can be explained
by the protective effect of estrogen.47 However,
this relationship was not observed in the Women’s
Health Initiative Memory Study.78 In addition, the
decreased endogenous estrogen level was related
to an increased risk of AD.72 However, no associ-
ation was observed in other studies.79,80 Peri-
menopausal women are at a relatively young age,
which has a lower risk of dementia, and experience
complicated physiological changes. The hetero-
geneity of HRT, different study designs, and many
other factors could confound the association be-
tween HRT and the risk of dementia and explain
previous inconsistent findings. A well-defined
cohort study would help to elucidate the rela-
tionship between HRT and the risk of dementia.
Animal studies have reported that some non-
steroidal anti-inflammatory drugs (NSAIDs) can
lower the level of Aβ-42,81 which is independent of
cyclooxygenase activity,82 and long-term NSAIDs
exposure can lower the risk and slow down pro-
gression of AD.8,83 A meta-analysis of four prospec-
tive studies has found that lifetime NSAID
exposure was associated with a 26% reduction in
risk of AD. A meta-analysis of three prospective
studies has shown that use of NSAIDs for ≥ 2
years contributed to a 58% reduction in risk of
dementia.84 However, some randomized clinical
trials have failed to demonstrate this associa-
tion.85–87 A recent cohort study has confirmed
the protective effect of NSAIDs on the risk of AD
[hazard ratio, 0.63; 95% confidence interval (CI),
0.45–0.88].88 Few randomized clinical trials are
available to evaluate the effect of NSAIDs on de-
mentia because of their potential cardiovascular
side effects.89,90 More observational studies are
needed to confirm the association between use
of NSAIDs and risk of dementia. In addition,
drug–drug interactions need to be considered to
rule out the confounding effect from other med-
ications. To date, the mechanism of protection
against dementia by NSAIDs is not clearly 
understood.91,92
Education
In a follow-up study, subjects with less education
had a higher risk of non-AD dementia [odds ratio
(OR), 1.75; 95% CI, 1.03–2.98] as compared with
those with a high school diploma.93 However,
this association was not observed for AD.93 In
addition to childhood education, less post-
secondary education (i.e. education beyond high
school or 12th-grade level) was significantly asso-
ciated with an increased risk of dementia after
the age of 60 years.94 Similarly, a study in the
United States has found that Caucasians with
low education level (≤ 10 years) had twice the
risk of dementia of those with high education
level (> 10 years).95 A cohort study has reported a
significant association between education level
and cognitive function, but the association was
not significant between education and rate of
cognitive decline.96 It is possible that individuals
with lower education level tend to have lower
cognitive function compared with those at the
same age but with higher education level. There-
fore, the onset of dementia among the former is
likely to be earlier than that in the latter. As a
J.H. Chen, et al
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whole, education level is related to socioeco-
nomic status97 and sex,47 both of which may
complicate the association between education
level and risk of dementia. The different cutoff
points of the education level between studies,
and failure to explore the association by demen-
tia subtypes in some studies, could explain previ-
ous controversial findings.
Alcohol Consumption
Alcohol intake seems to protect older people
from dementia, including AD, in a J-shape asso-
ciation.98 A recent meta-analysis, including 20
cohorts and three nested case–control studies,
has indicated that alcohol drinking may be pro-
tective for AD and dementia, but not for VaD and
cognitive decline.99 However, some studies have
shown that heavy alcohol consumption might
be associated with an increased risk of dementia
in patients with mild cognitive impairment or in
men carrying the APOEe4 allele.100,101 In con-
trast, the consumption of liquor, beer, and total
alcohol is not associated with a decreased risk of
AD.102 Decreased risk of AD is associated with
wine consumption of up to three servings daily
among individuals aged ≥ 65 years without the
APOEe4 allele.102 Controversial findings in previ-
ous studies could have resulted from different
types of alcohol (e.g. liquor, beer or wine), dif-
ferent follow-up time, measurement of alcohol
consumption, and other confounding factors.
More studies with more accurate measurement
are needed to confirm this association.
Body Mass Index (BMI)
Overweight and obesity are risk factors of AD,
hyperinsulinemia and diabetes.103 A recent meta-
analysis,104 including 10 follow-up studies with
subjects aged 40–80 years at baseline, has shown
a U-shape relationship between BMI and demen-
tia.104 However, a recent follow-up study105 has
demonstrated an increased risk of dementia among
obese persons (BMI > 30), as compared with those
with normal weight (BMI 20–25) at 50 years of
age. Whereas, there was a reverse association be-
tween BMI and risk of dementia at ≥ 65 years of
age.105 In contrast, weight gain and increased waist
circumference and skinfold thickness are related
to increased risk of dementia.104 Another study has
found that steady annual weight loss of 1 kg/m2
among old people was related to a 35% increase
in AD risk, as compared with individuals without
BMI changes.106 Weight loss can reflect underlying
diseases and obesity can be related to subsequent
vascular diseases. Old people experience muscle
loss, therefore, waist circumference rather than
BMI might be a better surrogate of overweight or
obesity. This could explain partly the controver-
sial findings from previous studies.
Comorbidity
Dementia risk is related to various diseases. Hyper-
tension is an important risk factor for VaD107 but
not AD.108 Type 2 diabetes is associated strongly
with insulin resistance, which is related to the
formation of Aβ and inflammatory agents in the
brain,109,110 and the subsequent increased risk of
AD.109 On average, around half of individuals with
vascular cognitive impairment might develop 
dementia within 5 years after a stroke.111 In addi-
tion, there is an increased risk of dementia among
individuals > 84 years old and who have had two
or more infections in the 4 years preceding diag-
nosis of dementia compared to those who have
had zero or one infection.112 Human immuno-
deficiency virus and hepatitis C virus have been
reported to be associated with dementia.113,114
Moreover, traumatic brain injury can induce the
early development of AD.115 A meta-analysis that
included 15 case–control studies has found that
head injury is associated with an elevated risk of
AD among men but not women.116 Men tend to
be involved with more dangerous work than
women, and therefore have a higher risk of head
injury and subsequent increased risk of dementia
than do women. Furthermore, two meta-analyses
Dementia and risk factors
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have shown consistently that a history of depres-
sion is a risk factor for AD in later life.117,118 As 
a whole, infections, vascular factors and related
diseases, head injury, and psychological condi-
tions can share a common inflammatory pathway
that contributes to the etiology of dementia.
Environmental Factors
The role of environmental factors on the progress
of dementia is complicated. Aluminum is related
to the risk of dementia because it can act as a co-
factor in the progression of dementia.119,120 It has
been speculated that other metals, such as iron,
copper and zinc, are related to dementia.119,121–123
Several nutrients have also been linked with the
risk of dementia. For example, serum vitamin D
level is lower among women with mild dementia
than among those without.124 In addition, a clin-
ical trial has shown that vitamin E is not benefi-
cial to patients with mild cognitive impairment
at a stage between normal aging and early stages
of dementia.125 Some macronutrients, such as
glucose, protein (tryptophan and tyrosine) and
unsaturated fatty acids, have been linked to 
age-related changes in cognitive function among
people with AD and VaD.119 Dementia can be ex-
acerbated via oxidative stress as a result of higher
energy and lower antioxidant intake.126 People
with AD or VaD have similar dietary patterns, 
except that the former consume more animal fats
than the latter.126 In addition, excessive intake of
n-6 polyunsaturated fatty acids (PUFAs) or defi-
ciency of n-3 PUFAs may lead to chronic inflam-
mation, platelet aggregation, or microvascular
endothelial dysfunction.126 Environmental expo-
sure before the onset of dementia may be influ-
ential and many environmental factors are yet to
be identified.
Conclusions
Dementia is a complex human disease and many
factors contribute to its pathogenesis. As a result
of improved health care and changes in lifestyle,
longer life spans have led to an increasing num-
ber of people with dementia. In the post-genome
era, the advance of high-throughput genotyping
technology, e.g. microarrays, and statistical tools
have allowed us to extensively assess the associa-
tion between genetic factors and risk of dementia.
Environmental factors, which have not been well
identified, might also play an important role in the
pathogenesis of dementia. Future research should
place an emphasis on identifying new environ-
mental risk factors, perform whole-genome asso-
ciation studies at different levels (DNA, RNA and
protein), explore the interaction between genetic
and environmental factors, and include non-
Caucasian populations, to unravel the etiology
of dementia.
References
1. Hoyert DL, Kung HC, Smith BL. Deaths: preliminary data
for 2003. Natl Vital Stat Rep 2005;53:1–48.
2. The World Factbook. Washington, DC: Central Intelligence
Agency, 2007.
3. Albert MS. Changing the trajectory of cognitive decline? 
N Engl J Med 2007;357:502–3.
4. Walsh DM, Selkoe DJ. Deciphering the molecular basis of
memory failure in Alzheimer’s disease. Neuron 2004;44:
181–93.
5. Liu CK, Tai CT, Lin RT, et al. Epidemiology of dementia in
Taiwan. Appl Psychol Res 2000;7:157–69.
6. Basics of Alzheimer’s Disease: What It Is and What You
Can Do. Chicago, IL: Alzheimer’s Association, 2005:
8–9.
7. Selkoe DJ. Defining molecular targets to prevent Alzheimer
disease. Arch Neurol 2005;62:192–5.
8. Heneka MT, O’Banion MK. Inflammatory processes in
Alzheimer’s disease. J Neuroimmunol 2007;184:69–91.
9. Wong PC, Cai H, Borchelt DR, et al. Genetically engi-
neered mouse models of neurodegenerative diseases.
Nat Neurosci 2002;5:633–9.
10. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted
oligomers of amyloid beta protein potently inhibit hippo-
campal long-term potentiation in vivo. Nature 2002;
416:535–9.
11. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo mea-
surement of activated microglia in dementia. Lancet 2001;
358:461–7.
12. Heneka MT, Sastre M, Dumitrescu-Ozimek L, et al. Focal
glial activation coincides with increased BACE1 activation 
J.H. Chen, et al
760 J Formos Med Assoc | 2009 • Vol 108 • No 10
and precedes amyloid plaque deposition in APP[V717I]
transgenic mice. J Neuroinflammation 2005;2:22.
13. Moechars D, Dewachter I, Lorent K, et al. Early phenotypic
changes in transgenic mice that overexpress different mu-
tants of amyloid precursor protein in brain. J Biol Chem
1999;274:6483–92.
14. Hu J, Akama KT, Krafft GA, et al. Amyloid-beta peptide
activates cultured astrocytes: morphological alterations,
cytokine induction and nitric oxide release. Brain Res
1998;785:195–206.
15. Lindberg C, Selenica ML, Westlind-Danielsson A, et al.
Beta-amyloid protein structure determines the nature of
cytokine release from rat microglia. J Mol Neurosci 2005;
27:1–12.
16. White JA, Manelli AM, Holmberg KH, et al. Differential
effects of oligomeric and fibrillar amyloid-beta 1-42 on 
astrocyte-mediated inflammation. Neurobiol Dis 2005;18:
459–65.
17. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene
dose of apolipoprotein E type 4 allele and the risk of
Alzheimer’s disease in late onset families. Science 1993;
261:921–3.
18. Gatz M, Fratiglioni L, Johansson B, et al. Complete ascer-
tainment of dementia in the Swedish Twin Registry: the
HARMONY study. Neurobiol Aging 2005;26:439–47.
19. Pedersen NL, Gatz M, Berg S, et al. How heritable is
Alzheimer’s disease late in life? Findings from Swedish
twins. Ann Neurol 2004;55:180–5.
20. Richard F, Amouyel P. Genetic susceptibility factors for
Alzheimer’s disease. Eur J Pharmacol 2001;412:1–12.
21. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex,
and ethnicity on the association between apolipoprotein E
genotype and Alzheimer disease. A meta-analysis. APOE
and Alzheimer Disease Meta Analysis Consortium. JAMA
1997;278:1349–56.
22. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apo-
lipoprotein E: high-avidity binding to beta-amyloid and in-
creased frequency of type 4 allele in late-onset familial
Alzheimer disease. Proc Natl Acad Sci USA 1993;90:
1977–81.
23. Pastor P, Goate AM. Molecular genetics of Alzheimer’s
disease. Curr Psychiatry Rep 2004;6:125–33.
24. Du Y, Dodel RC, Eastwood BJ, et al. Association of an in-
terleukin 1 alpha polymorphism with Alzheimer’s disease.
Neurology 2000;55:480–3.
25. Hedley R, Hallmayer J, Groth DM, et al. Association of 
interleukin-1 polymorphisms with Alzheimer’s disease in
Australia. Ann Neurol 2002;51:795–7.
26. Griffin WS, Mrak RE. Interleukin-1 in the genesis and pro-
gression of and risk for development of neuronal degener-
ation in Alzheimer’s disease. J Leukoc Biol 2002;72:233–8.
27. Nicoll JA, Mrak RE, Graham DI, et al. Association of 
interleukin-1 gene polymorphisms with Alzheimer’s 
disease. Ann Neurol 2000;47:365–8.
28. McCusker SM, Curran MD, Dynan KB, et al. Association be-
tween polymorphism in regulatory region of gene encoding
tumour necrosis factor alpha and risk of Alzheimer’s dis-
ease and vascular dementia: a case–control study. Lancet
2001;357:436–9.
29. McGeer PL, McGeer EG. Polymorphisms in inflammatory
genes and the risk of Alzheimer disease. Arch Neurol
2001;58:1790–2.
30. Abraham R, Moskvina V, Sims R, et al. A genome-wide
association study for late-onset Alzheimer’s disease using
DNA pooling. BMC Med Genomics 2008;1:44.
31. Bertram L, Lange C, Mullin K, et al. Genome-wide associ-
ation analysis reveals putative Alzheimer’s disease suscep-
tibility loci in addition to APOE. Am J Hum Genet 2008;
83:623–32.
32. Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation
in PCDH11X is associated with susceptibility to late-onset
Alzheimer’s disease. Nat Genet 2009;41:192–8.
33. Kukull WA, Higdon R, Bowen JD, et al. Dementia and
Alzheimer disease incidence: a prospective cohort study.
Arch Neurol 2002;59:1737–46.
34. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk
factors for dementia and Alzheimer’s disease: results from
EURODEM pooled analyses. EURODEM Incidence
Research Group and Work Groups. European Studies of
Dementia. Neurology 1999;52:78–84.
35. Ganguli M, Dodge HH, Chen P, et al. Ten-year incidence
of dementia in a rural elderly US community population:
the MoVIES Project. Neurology 2000;54:1109–16.
36. Rocca WA, Cha RH, Waring SC, et al. Incidence of de-
mentia and Alzheimer’s disease: a reanalysis of data from
Rochester, Minnesota, 1975–1984. Am J Epidemiol 1998;
148:51–62.
37. Bachman DL, Wolf PA, Linn RT, et al. Incidence of demen-
tia and probable Alzheimer’s disease in a general popula-
tion: the Framingham Study. Neurology 1993;43:515–9.
38. Kawas C, Gray S, Brookmeyer R, et al. Age-specific inci-
dence rates of Alzheimer’s disease: the Baltimore Longitu-
dinal Study of Aging. Neurology 2000;54:2072–7.
39. Lopez-Pousa S, Vilalta-Franch J, Llinas-Regla J, et al.
Incidence of dementia in a rural community in Spain: the
Girona cohort study. Neuroepidemiology 2004;23:170–7.
40. Liu L, Guo XE, Zhou YQ, et al. Prevalence of dementia in
China. Dement Geriatr Cogn Disord 2003;15:226–30.
41. Urakami K, Adachi Y, Takahashi K. A community-based
study of parental age at the birth of patients with demen-
tia of the Alzheimer type. Arch Neurol 1989;46:38–9.
42. Corkin S, Growdon JH, Rasmussen SL. Parental age as a risk
factor in Alzheimer’s disease. Ann Neurol 1983;13:674–6.
43. Bertram L, Busch R, Spiegl M, et al. Paternal age is a risk
factor for Alzheimer disease in the absence of a major gene.
Neurogenetics 1998;1:277–80.
44. Corkin S, Growdon JH, Rasmussen SL. Parental age as a risk
factor in Alzheimer’s disease. Ann Neurol 1983;13:674–6.
45. Jouan-Flahault C, Seroussi MC, Colvez A. Absence of a 
relationship between senile dementia and parental age. 
A case report survey in Upper Normandy. Rev Epidemiol
Sante Publique 1989;37:73–5. [In French]
Dementia and risk factors
J Formos Med Assoc | 2009 • Vol 108 • No 10 761
46. Ptok U, Papassotiropoulos A, Maier W, et al. Advanced
parental age: a risk factor for Alzheimer’s disease or de-
pression in the elderly? Int Psychogeriatr 2000;12:445–51.
47. Andersen K, Launer LJ, Dewey ME, et al. Gender differ-
ences in the incidence of AD and vascular dementia: the
EURODEM Studies. EURODEM Incidence Research Group.
Neurology 1999;53:1992–7.
48. Ruitenberg A, Ott A, van Swieten JC, et al. Incidence of
dementia: does gender make a difference? Neurobiol Aging
2001;22:575–80.
49. Ravaglia G, Forti P, Maioli F, et al. Incidence and etiology of
dementia in a large elderly Italian population. Neurology
2005;64:1525–30.
50. Yaffe K, Barnes D, Nevitt M, et al. A prospective study of
physical activity and cognitive decline in elderly women:
women who walk. Arch Intern Med 2001;161:1703–8.
51. Barnes DE, Yaffe K, Satariano WA, et al. A longitudinal
study of cardiorespiratory fitness and cognitive function in
healthy older adults. J Am Geriatr Soc 2003;51:459–65.
52. Karp A, Paillard-Borg S, Wang HX, et al. Mental, physical
and social components in leisure activities equally con-
tribute to decrease dementia risk. Dement Geriatr Cogn
Disord 2006;21:65–73.
53. Laurin D, Verreault R, Lindsay J, et al. Physical activity and
risk of cognitive impairment and dementia in elderly 
persons. Arch Neurol 2001;58:498–504.
54. Abbott RD, White LR, Ross GW, et al. Walking and demen-
tia in physically capable elderly men. JAMA 2004;292:
1447–53.
55. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise
training on elderly persons with cognitive impairment and
dementia: a meta-analysis. Arch Phys Med Rehabil
2004;85:1694–704.
56. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of phys-
ical activity on cognitive function in older adults at risk for
Alzheimer disease: a randomized trial. JAMA 2008;300:
1027–37.
57. Reuben DB, Judd-Hamilton L, Harris TB, et al. The associ-
ations between physical activity and inflammatory mark-
ers in high-functioning older persons: MacArthur Studies
of Successful Aging. J Am Geriatr Soc 2003;51:1125–30.
58. Barnes DE, Whitmer RA, Yaffe K. Physical activity and de-
mentia: the need for prevention trials. Exerc Sport Sci Rev
2007;35:24–9.
59. Podewils LJ, Guallar E, Kuller LH, et al. Physical activity,
APOE genotype, and dementia risk: findings from the
Cardiovascular Health Cognition Study. Am J Epidemiol
2005;161:639–51.
60. Peters R, Poulter R, Warner J, et al. Smoking, dementia
and cognitive decline in the elderly, a systematic review.
BMC Geriatr 2008;8:36.
61. Aggarwal NT, Bienias JL, Bennett DA, et al. The relation of
cigarette smoking to incident Alzheimer’s disease in a
biracial urban community population. Neuroepidemiology
2006;26:140–6.
62. Merchant C, Tang MX, Albert S, et al. The influence of
smoking on the risk of Alzheimer’s disease. Neurology
1999;52:1408–12.
63. Juan D, Zhou DH, Li J, et al. A 2-year follow-up study of
cigarette smoking and risk of dementia. Eur J Neurol
2004;11:277–82.
64. Lagnaoui R, Begaud B, Moore N, et al. Benzodiazepine
use and risk of dementia: a nested case–control study. 
J Clin Epidemiol 2002;55:314–8.
65. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins re-
duce risk of incident dementia and Alzheimer disease? The
Cache County Study. Arch Gen Psychiatry 2005;62:217–24.
66. Wolozin B, Wang SW, Li NC, et al. Simvastatin is associ-
ated with a reduced incidence of dementia and Parkinson’s
disease. BMC Med 2007;5:20.
67. Forette F, Seux ML, Staessen JA, et al. Prevention of de-
mentia in randomised double-blind placebo-controlled
Systolic Hypertension in Europe (Syst-Eur) trial. Lancet
1998;352:1347–51.
68. Tzourio C, Anderson C, Chapman N, et al. Effects of
blood pressure lowering with perindopril and indapamide
therapy on dementia and cognitive decline in patients with
cerebrovascular disease. Arch Intern Med 2003;163:
1069–75.
69. Lithell H, Hansson L, Skoog I, et al. The Study on
Cognition and Prognosis in the Elderly (SCOPE): principal
results of a randomized double-blind intervention trial. 
J Hypertens 2003;21:875–86.
70. Applegate WB, Pressel S, Wittes J, et al. Impact of the
treatment of isolated systolic hypertension on behavioral
variables. Results from the systolic hypertension in the
elderly program. Arch Intern Med 1994;154:2154–60.
71. Forette F, Seux ML, Staessen JA, et al. The prevention of
dementia with antihypertensive treatment: new evidence
from the Systolic Hypertension in Europe (Syst-Eur) study.
Arch Intern Med 2002;162:2046–2.
72. Paganini-Hill A, Henderson VW. Estrogen deficiency and
risk of Alzheimer’s disease in women. Am J Epidemiol
1994;140:256–61.
73. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen dur-
ing menopause on risk and age at onset of Alzheimer’s
disease. Lancet 1996;348:429–32.
74. Kawas C, Resnick S, Morrison A, et al. A prospective
study of estrogen replacement therapy and the risk 
of developing Alzheimer’s disease: the Baltimore
Longitudinal Study of Aging. Neurology 1997;48:
1517–21.
75. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in
postmenopausal women: effects on cognitive function
and dementia. JAMA 1998;279:688–95.
76. Waring SC, Rocca WA, Petersen RC, et al. Postmenopausal
estrogen replacement therapy and risk of AD: a population-
based study. Neurology 1999;52: 965–70.
77. Zandi PP, Carlson MC, Plassman BL, et al. Hormone re-
placement therapy and incidence of Alzheimer disease in 
J.H. Chen, et al
762 J Formos Med Assoc | 2009 • Vol 108 • No 10
older women: the Cache County Study. JAMA 2002;288:
2123–9.
78. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus
progestin and the incidence of dementia and mild cogni-
tive impairment in postmenopausal women: the Women’s
Health Initiative Memory Study: a randomized controlled
trial. JAMA 2003;289:2651–62.
79. Barrett-Connor E, Kritz-Silverstein D. Estrogen replace-
ment therapy and cognitive function in older women.
JAMA 1993;269:2637–41.
80. Matthews K, Cauley J, Yaffe K, et al. Estrogen replace-
ment therapy and cognitive decline in older community
women. J Am Geriatr Soc 1999;47:518–23.
81. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enan-
tiomers of flurbiprofen target gamma-secretase and
lower Abeta 42 in vivo. J Clin Invest 2003;112:440–9.
82. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs
lower amyloidogenic Abeta42 independently of cyclo-
oxygenase activity. Nature 2001;414:212–6.
83. Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal
anti-inflammatory drugs in Alzheimer’s disease. Neurology
1995;45:51–5.
84. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-
inflammatory drugs for the prevention of Alzheimer’s
disease: a systematic review. Neuroepidemiology 2004;
23:159–69.
85. Wyss-Coray T. Inflammation in Alzheimer disease: driv-
ing force, bystander or beneficial response? Nat Med
2006;12:1005–15.
86. Aisen PS, Schafer KA, Grundman M, et al. Effects of ro-
fecoxib or naproxen vs placebo on Alzheimer disease
progression: a randomized controlled trial. JAMA 2003;
289:2819–26.
87. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-
blind, study of rofecoxib in patients with mild cognitive
impairment. Neuropsychopharmacology 2005;30:
1204–15.
88. Szekely CA, Breitner JC, Fitzpatrick AL, et al. NSAID use
and dementia risk in the Cardiovascular Health Study: role
of APOE and NSAID type. Neurology 2008;70:17–24.
89. Scharf JM, Daffner KR. NSAIDs in the prevention of 
dementia: a Cache-22? Neurology 2007;69:235–6.
90. ADAPT Research Group. Cardiovascular and cerebrovas-
cular events in the randomized, controlled Alzheimer’s
Disease Anti-Inflammatory Prevention Trial (ADAPT).
PLoS Clin Trials 2006;1:e33.
91. Yan Q, Zhang J, Liu H, et al. Anti-inflammatory drug therapy
alters beta-amyloid processing and deposition in an animal
model of Alzheimer’s disease. J Neurosci 2003;23:7504–9.
92. Zilka N, Ferencik M, Hulin I. Neuroinflammation in
Alzheimer’s disease: protector or promoter? Bratisl Lek
Listy 2006;107:374–83.
93. Cobb JL, Wolf PA, Au R, et al. The effect of education on
the incidence of dementia and Alzheimer’s disease in
the Framingham Study. Neurology 1995;45:1707–12.
94. Chibnall JT, Eastwood R. Postsecondary education and
dementia risk in older Jesuit priests. Int Psychogeriatr
1998;10:359–68.
95. Shadlen MF, Siscovick D, Fitzpatrick AL, et al. Education,
cognitive test scores, and black-white differences in 
dementia risk. J Am Geriatr Soc 2006;54:898–905.
96. Wilson RS, Hebert LE, Scherr PA, et al. Educational at-
tainment and cognitive decline in old age. Neurology
2009;72:460–5.
97. Karp A, Kareholt I, Qiu C, et al. Relation of education 
and occupation-based socioeconomic status to incident
Alzheimer’s disease. Am J Epidemiol 2004;159:175–83.
98. O’Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovas-
cular health: the razor-sharp double-edged sword. J Am
Coll Cardiol 2007;50:1009–14.
99. Peters R, Peters J, Warner J, et al. Alcohol, dementia and
cognitive decline in the elderly: a systematic review. 
Age Ageing 2008;37:505–12.
100. Mukamal KJ, Kuller LH, Fitzpatrick AL, et al. Prospective
study of alcohol consumption and risk of dementia in
older adults. JAMA 2003;289:1405–13.
101. Xu G, Liu X, Yin Q, et al. Alcohol consumption and tran-
sition of mild cognitive impairment to dementia.
Psychiatry Clin Neurosci 2009;63:43–9.
102. Luchsinger JA, Tang MX, Siddiqui M, et al. Alcohol intake
and risk of dementia. J Am Geriatr Soc 2004;52:540–6.
103. Luchsinger JA, Mayeux R. Adiposity and Alzheimer’s dis-
ease. Curr Alzheimer Res 2007;4:127–34.
104. Beydoun MA, Beydoun HA, Wang Y. Obesity and central
obesity as risk factors for incident dementia and its sub-
types: a systematic review and meta-analysis. Obes Rev
2008;9:204–18.
105. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Midlife and
late-life obesity and the risk of dementia: cardiovascular
health study. Arch Neurol 2009;66:336–42.
106. Buchman AS, Wilson RS, Bienias JL, et al. Change in
body mass index and risk of incident Alzheimer disease.
Neurology 2005;65:892–7.
107. Forette F, Boller F. Hypertension and the risk of demen-
tia in the elderly. Am J Med 1991;90:14S–9S.
108. Posner HB, Tang MX, Luchsinger J, et al. The relationship
of hypertension in the elderly to AD, vascular dementia,
and cognitive function. Neurology 2002;58:1175–81.
109. Craft S. Insulin resistance and Alzheimer’s disease
pathogenesis: potential mechanisms and implications
for treatment. Curr Alzheimer Res 2007;4:147–52.
110. Sun MK, Alkon DL. Links between Alzheimer’s disease
and diabetes. Drugs Today (Barc) 2006;42:481–9.
111. Starkstein SE, Almeida OP. Understanding cognitive im-
pairment and dementia: stroke study. Curr Opin
Psychiatry 2003;16:615–20.
112. Dunn N, Mullee M, Perry VH, et al. Association 
between dementia and infectious disease: evidence
from a case– control study. Alzheimer Dis Assoc Disord
2005;19:91–4.
Dementia and risk factors
J Formos Med Assoc | 2009 • Vol 108 • No 10 763
113. Corder EH, Robertson K, Lannfelt L, et al. HIV-infected
subjects with the E4 allele for APOE have excess demen-
tia and peripheral neuropathy. Nat Med 1998;4:1182–4.
114. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C
and cognitive impairment in a cohort of patients with
mild liver disease. Hepatology 2002;35:433–9.
115. Lye TC, Shores EA. Traumatic brain injury as a risk factor
for Alzheimer’s disease: a review. Neuropsychol Rev
2000;10:115–29.
116. Fleminger S, Oliver DL, Lovestone S, et al. Head injury as
a risk factor for Alzheimer’s disease: the evidence 10 years
on; a partial replication. J Neurol Neurosurg Psychiatry
2003;74:857–62.
117. Ownby RL, Crocco E, Acevedo A, et al. Depression and
risk for Alzheimer disease: systematic review, meta-
analysis, and metaregression analysis. Arch Gen Psychiatry
2006;63:530–8.
118. Jorm AF. History of depression as a risk factor for 
dementia: an updated review. Aust N Z J Psychiatry
2001;35:776–81.
119. Solfrizzi V, Colacicco AM, D’Introno A, et al. Macro-
nutrients, aluminium from drinking water and foods,
and other metals in cognitive decline and dementia. 
J Alzheimers Dis 2006;10:303–30.
120. Rondeau V, Commenges D, Jacqmin-Gadda H, et al.
Relation between aluminum concentrations in drinking
water and Alzheimer’s disease: an 8-year follow-up
study. Am J Epidemiol 2000;152:59–66.
121. Yonekawa M, Okabe T, Asamoto Y, et al. A case of
hereditary ceruloplasmin deficiency with iron deposition
in the brain associated with chorea, dementia, diabetes
mellitus and retinal pigmentation: administration of fresh-
frozen human plasma. Eur Neurol 1999;42:157–62.
122. Danscher G, Jensen KB, Frederickson CJ, et al. Increased
amount of zinc in the hippocampus and amygdala of
Alzheimer’s diseased brains: a proton-induced X-ray
emission spectroscopic analysis of cryostat sections from
autopsy material. J Neurosci Methods 1997;76:53–9.
123. Shore D, Henkin RI, Nelson NR, et al. Hair and serum
copper, zinc, calcium, and magnesium concentrations in
Alzheimer-type dementia. J Am Geriatr Soc 1984;32:
892–5.
124. Kipen E, Helme RD, Wark JD, et al. Bone density, vitamin
D nutrition, and parathyroid hormone levels in women
with dementia. J Am Geriatr Soc 1995;43:1088–91.
125. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E
and donepezil for the treatment of mild cognitive 
impairment. N Engl J Med 2005;352:2379–88.
126. Otsuka M, Yamaguchi K, Ueki A. Similarities and differ-
ences between Alzheimer’s disease and vascular de-
mentia from the viewpoint of nutrition. Ann NY Acad Sci
2002;977:155–61.
J.H. Chen, et al
764 J Formos Med Assoc | 2009 • Vol 108 • No 10
